NMD Pharma A/S

NMD Pharma, a Danish biotechnology company, discovers and develops novel therapeutics for neuromuscular diseases using an experimental platform focusing on ion channel function and electrophysiology of skeletal muscle; it is headquartered in Denmark.

Here are key aspects of the company:

• Products & Services: The company develops small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels to address conditions where muscle activation fails, leading to weakness and excessive fatigue.
• Industries: NMD Pharma focuses on treating neuromuscular diseases including myasthenia gravis, spinal muscular atrophy, Charcot-Marie-Tooth disease, and sarcopenia.
• Innovation: The firm utilizes a unique experimental platform that selectively targets skeletal muscle to create first-in-class therapies with promising therapeutic potential for patients lacking independence.

NMD Pharma has secured approximately $180M from leading life sciences investors to advance its dynamic portfolio of small molecule therapies, earning recognition such as the EY Entrepreneur Of The Year 2022 in Life Sciences and the INCUBA award for Startup of the Year 2022.